Associated Papers
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.
Herencia-Ropero A et al.
Genome Medicine, 2024
39187844 (PubMed )
Supplement: 13073_2024_1370_MOESM3_ESM.xlsx › SNV
Establishment and Comprehensive Characterization of a Novel Preclinical Platform of Metastatic Retinoblastoma for Therapeutic Developments.
Zugbi S et al.
Investigative Ophthalmology & Visual Science, 2023
38117242 (PubMed )
Supplement: iovs-64-15-27_s002.xlsx › Supplementary_Table_2
Select a paper to view details